Skip to main content
Home > Week in Review > Clinical Results

Chronological Index of BioCentury, Week in Review: Clinical Results

BioCentury, Week in Review Current Issue
  • [18F]-flutemetamol diagnostic data

    General Electric Co. (NYSE:GE), Fairfield, Conn. Product: [18F]-flutemetamol (GE-067, AH110690, flutemetamol) Business: Diagnostic Molecular target: Beta amyloid Description: Pittsburgh compound B derivative for in vivo…

    Published on 1/30/2012
  • AAV1-gamma-sarcoglycan gene therapy: Phase I data

    Hopital Pitie-Salpetriere, Paris, France Product: AAV1-gamma-sarcoglycan gene therapy Business: Musculoskeletal Molecular target: Not applicable Description: Adeno-associated virus (AAV) encoding the gamma-sarcoglycan …

    Published on 1/30/2012
  • ADXS-HPV: Additional Phase II data

    Advaxis Inc. (OTCBB:ADXS), North Brunswick, N.J. Product: ADXS-HPV (ADXS11-001) (formerly Lovaxin C) Business: Cancer Molecular target: Not applicable Description: Live Listeria monocytogenes-expressing HPV type 16 E7 …

    Published on 1/30/2012
  • Avastin bevacizumab: Phase III data

    Genentech Inc., South San Francisco, Calif. Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), Tokyo, Japan Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: Avastin bevacizumab (RG435) Business: Cancer Molecular …

    Published on 1/30/2012
  • Cabozantinib: Interim Phase II data

    Exelixis Inc. (NASDAQ:EXEL), South San Francisco, Calif. Product: Cabozantinib (XL184) Business: Cancer Molecular target: Vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) (VEGFR-2); c-Met receptor …

    Published on 1/30/2012
  • Clivatuzumab-based blood test diagnostic data

    Immunomedics Inc. (NASDAQ:IMMU), Morris Plains, N.J. Product: Clivatuzumab-based blood test Business: Diagnostic Molecular target: Mucin 1 (MUC1) (CD227) Description: Blood-based test that detects MUC1 Indication: …

    Published on 1/30/2012
  • Everolimus: Phase III data

    Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Everolimus (Afinitor, Certican, Zortress, Votubia) (RAD001) Business: Cancer Molecular target: Mammalian target of rapamycin (mTOR) (FRAP) (RAFT1) …

    Published on 1/30/2012
  • Gardasil: Postmarketing study data

    Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Gardasil Business: Infectious Molecular target: Not applicable Description: HPV types 6, 11, 16 and 18 …

    Published on 1/30/2012
  • IMO-2055: Additional Phase Ib data

    Idera Pharmaceuticals Inc. (NASDAQ:IDRA), Cambridge, Mass. Product: IMO-2055, EMD 1201081 Business: Cancer Molecular target: Toll-like receptor 9 (TLR9) Description: Second-generation synthetic immune modulatory …

    Published on 1/30/2012
  • LDE225: Development discontinued

    Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: LDE225 Business: Cancer Molecular target: Smoothened (SMO) Description: Smoothened (SMO) inhibitor Indication: Treat nevoid basal cell carcinoma syndrome (…

    Published on 1/30/2012
  • MA09-hRPE cells: Preliminary Phase I/II data

    Advanced Cell Technology Inc. (OTCBB:ACTC), Santa Monica, Calif. Product: MA09-hRPE cells (hESC-derived hRPE cells) Business: Ophthalmic Molecular target: Not applicable Description: Human embryonic stem cell-derived …

    Published on 1/30/2012
  • MA09-hRPE cells: Preliminary Phase I/II data

    Advanced Cell Technology Inc. (OTCBB:ACTC), Santa Monica, Calif. Product: MA09-hRPE cells (hESC-derived hRPE cells) Business: Ophthalmic Molecular target: Not applicable Description: Human embryonic stem cell-derived …

    Published on 1/30/2012
  • Oncotype DX colon cancer assay: Postmarketing study data

    Genomic Health Inc. (NASDAQ:GHDX), Redwood City, Calif. Product: Oncotype DX colon cancer assay Business: Diagnostic Molecular target: NA Description: Diagnostic assay that analyzes expression of 12 genes to generate a …

    Published on 1/30/2012
  • Recombinant botulism vaccine: Phase II data

    DynPort Vaccine Co. LLC, Frederick, Md. Product: Recombinant botulism vaccine, rBV A/B Business: Infectious Molecular target: Not applicable Description: Recombinant botulinum neurotoxin serotypes A and B vaccine …

    Published on 1/30/2012
  • Saridegib: Interim Phase Ib/II data

    Infinity Pharmaceuticals Inc. (NASDAQ:INFI), Cambridge, Mass. Mundipharma International Ltd., Cambridge, U.K. Product: Saridegib (IPI-926) Business: Cancer Molecular target: Smoothened (SMO) Description: Hedgehog …

    Published on 1/30/2012
  • Secukinumab: Phase II data

    Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Secukinumab (AIN457) Business: Autoimmune Molecular target: Interleukin-17 (IL-17) Description: Human mAb targeting IL-17 Indication: Treat psoriatic …

    Published on 1/30/2012
  • Secukinumab: Phase II data

    Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Secukinumab (AIN457) Business: Autoimmune Molecular target: Interleukin-17 (IL-17) Description: Human mAb targeting IL-17 Indication: Treat ankylosing …

    Published on 1/30/2012
  • Secukinumab: Phase II data

    Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Product: Secukinumab (AIN457) Business: Autoimmune Molecular target: Interleukin-17 (IL-17) Description: Human mAb targeting IL-17 Indication: Treat rheumatoid …

    Published on 1/30/2012
  • Tasimelteon: Preliminary Phase III data

    Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), Rockville, Md. Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Product: Tasimelteon (VEC-162) Business: Neurology Molecular target: Melatonin MT1 receptor; Melatonin MT2 …

    Published on 1/30/2012
  • Tesetaxel: Phase IIb data

    Genta Inc. (OTCBB:GNTA), Berkeley Heights, N.J. Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568), Tokyo, Japan Product: Tesetaxel (DJ-927) Business: Cancer Molecular target: Tubulin Description: Oral semi-synthetic …

    Published on 1/30/2012
  • Tysabri natalizumab: Postmarketing study data

    Biogen Idec Inc. (NASDAQ:BIIB), Weston, Mass. Elan Corp. plc (NYSE:ELN), Dublin, Ireland Product: Tysabri natalizumab Business: Autoimmune Molecular target: Integrin alpha(4) (VLA-4 ) (CD49D) Description: Humanized mAb …

    Published on 1/30/2012
  • Vertical Auto Profile diagnostic data

    Atherotech Diagnostics Lab Inc., Birmingham, Ala. Product: Vertical Auto Profile (VAP) Cholesterol Test Business: Diagnostic Molecular target: NA Description: Lipid profiling test that measures 22 cholesterol components…

    Published on 1/30/2012
  • Zevalin ibritumomab tiuxetan: Phase III data

    Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI), Henderson, Nev. Bayer AG (Xetra:BAYN), Leverkusen, Germany Product: Zevalin ibritumomab tiuxetan Business: Cancer Molecular target: CD20 Description: Yttrium-90-radiolabeled …

    Published on 1/30/2012
  • Belinostat: Phase I/II data

    Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI), Henderson, Nev. TopoTarget A/S (CSE:TOPO), Copenhagen, Denmark Product: Belinostat (IV PXD101) Business: Cancer Molecular target: Histone deacetylase (HDAC) Description: …

    Published on 1/23/2012
  • Candida vaccine: Additional Phase I data

    Pevion Biotech AG, Ittigen, Switzerland Product: Candida vaccine (PEV7) Business: Infectious Molecular target: NA Description: Candida vaccine based on the SAP2 protein antigen, a virulence factor of vulvovaginal …

    Published on 1/23/2012

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993

Log In


Forgot password  |  Forgot Login


If you are a subscriber, but have forgotten or have never received a password, please go here and ask us to send you a new one.

Week in Review

The biotech industry's most complete compendium of corporate, clinical and financial transactions provides an efficient surveillance system for:

  • Deals
  • Regulatory Events
  • Clinical Results
  • Financings
  • Management News

Need custom ComputerVision Software?